Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation.

Lei YanDavid BuiYuli LiNallakkandi RajeevanMazhgan RownekiKristin BerryStephanie ArgravesYuan HuangDenise M HynesFrancesca CunninghamGrant D HuangMihaela AslanGeorge N IoannouKristina L Bajema

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

Nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and death in older veterans, those at highest predicted risk for severe outcomes, and immunocompromised groups. Benefit was not observed in younger veterans or groups at lower predicted risk for hospitalization and death.

Keyphrases

clinical trial
antiretroviral therapy
type diabetes
metabolic syndrome
intensive care unit
adipose tissue
phase ii
community dwelling
weight loss
drug induced
open label